
Aldersrelateret kognitivt forfald
Alzheimers sygdom
Parkinsons sygdom
Kaffeindtag og neurodegenerative sygdomme
Referencer
1.
Singh-Manoux A et al (2011). Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. BMJ; 343:d7622 doi: 10.1136/bmj.d7622
2.
Alzheimer Europe (2010). Alzheimer’s disease. Available at http://www.alzheimer-europe.org/EN/Dementia/Alzheimer-s-disease
3.
Alzheimer Europe (2009). Who is affected by Alzheimer’s disease? Available at http://www.alzheimer-europe.org/index.php/Dementia/Alzheimer-s-disease/Who-is-affected-by-Alzheimer-s-disease
4.
Alzheimer Europe (2010). The impact of Alzheimer’s disease in Europe. Available at http://www.alzheimer-europe.org/EN/Research/PharmaCog/Why-Pharmacog/(language)/eng-GB
5.
European Parkinson’s Disease Association (2011). EPDA Annual report 2010-2011. Available at http://www.epda.eu.com/welcome/
6.
European Parkinson’s Disease Association (2011). Life with Parkinson’s. Available at http://www.epda.eu.com/welcome/
7.
Santos C et al (2010). Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis;20 Suppl 1:S187-204.
8.
Johnson-Kozlow M et al (2002). Coffee consumption and cognitive function among older adults. Am J Epidemiol;156:842-850.
9.
Ritchie K et al (2007). The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology;69:536-545.
10.
Barranco Quintana JL et al (2007). Alzheimer’s disease and coffee: a quantitative review. Neurol Res;29:91-5.
11.
Hernan MA et al (2002). A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol;52:276-84
12.
Costa J et al (2010). Caffeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis;20 Suppl 1:S221-38.
13.
Ascherio A et al (2001). Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol;50:56-63.
14.
Morelli M et al (2009). Adenosine A2A receptors and Parkinson’s disease. Handb Exp Pharmacol;193:589-615.
15.
Iida M et al (1999). Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res; 838:51-9.
16.
Larsson SC et al (2011). Coffee consumption and risk of stroke in women. Stroke;42:908-12.
17.
Larsson SC et al (2008). Coffee and tea consumption and risk of stroke subtypes in male smokers. Stroke;39:1681-7.
18.
Larsson SC & Orsini N (2011). Coffee consumption and risk of stroke: A dose-response meta-analysis of prospective studies. Am J Epidemiol; Sep 13. [Epub ahead of print]
Ja tak, jeg vil gerne modtage nyhedsbrev, når der er noget nyt om kaffe og helbred.